Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Moelis & Company heads into its October 28 earnings print in an unusual spot: the stock has shed nearly 19% over the past month, yet short sellers are not piling in, and the borrow market remains wide open.
The most telling story this week is on the Street. Analyst sentiment has turned more cautious, and the target-price compression is real. Goldman Sachs cut its target from $71 to $62 on October 1, maintaining a Neutral rating. UBS followed on October 7, upgrading from Sell to Neutral while trimming its target a further dollar to $59. Both moves land within $3 of the current price of $56.05, leaving essentially no cushion in their forecasts. Morgan Stanley remains the outlier, holding an Overweight with an $85 target after lifting it modestly to that level following Q2 results in July. The consensus sits at Hold with a mean target of $69.70, implying about 24% upside from here, but that figure is being dragged up by the Morgan Stanley outlier. Strip that out and the Street is effectively saying fair value is close to where the stock already trades.
The bear case rests on execution risk in M&A advisory. Despite Q2's record pipeline and a 41% sequential revenue jump to $307 million, sponsor backlog weakened as transactions were deferred. The bull case points to continued recruiting momentum and an M&A environment that should eventually normalise. Factor scores tell a similar mixed story: EPS momentum over 30 days ranks in the 83rd percentile, a strong reading, but forward earnings growth sits at the 50th percentile and the analyst recommendation differential ranks at just 46. The price-to-earnings multiple has compressed about 3.8 points over the past 30 days, now at roughly 15x, as the stock has de-rated faster than estimates have moved.
Short positioning does not corroborate the bearish price action. Short interest has been largely flat on the week, edging up just 0.08% to about 6.3% of the free float, a level that is meaningful but not extreme. The borrow market is exceptionally loose: availability has climbed back above 1,573%, meaning there are roughly 15 shares available to lend for every one currently borrowed. Cost to borrow is running at just 0.37%, down 17% over the past month. The ORTEX short score of 46.6 is mid-range and has barely moved over the past two weeks. This is not the setup of a market that is aggressively positioning for further downside, at least not through the short book.
On peers, the divergence this week is notable. Evercore gained 3.7% and TPG added 3.4% while Moelis fell 3.4%. PJT Partners moved almost in lockstep with Moelis, down 3.6%. The common thread between the underperformers appears to be pure-play advisory exposure. Firms with broader alternative asset management businesses, like KKR and Evercore, held up better on the week. That split suggests the market is specifically re-rating M&A advisory revenue rather than making a broad financial-sector call.
Institutional ownership is steady. BlackRock reported adding 647,000 shares as of September 30, lifting its stake to 12.2% of the company. State Street and Charles Schwab Investment Management also added modestly in the most recent period. Kayne Anderson Rudnick, one of the larger concentrated holders at 7.3%, trimmed 50,000 shares as of June 30. The recent insider activity is all compensation grants, small fractional awards to board directors in mid-September worth fewer than 100 shares combined across all recipients. None of it carries trading signal. Wikipedia attention for the stock has dropped well below its own 90-day average, a measure of retail interest that has been falling since early September.
With earnings due October 28, the question is less about whether the M&A pipeline is intact and more about whether transaction deferrals have spilled into Q3 revenues, and how the company characterises sponsor backlog momentum heading into 2027.
See the live data behind this article on ORTEX.
Open MC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
